Sunday, May 31, 2026Aggregating 2,418 sources · Updated 38 seconds agoNYC 54° · LON 47° · TOK 61°
Front PageWorld NewsTHE GUARDIAN
World News

Daily pill can double survival time for world’s deadliest cancer, trial shows

THE GUARDIAN·3h ago·3 min read
Photograph via The Guardian
RSS SUMMARY · AGGREGATED FROM THE GUARDIAN

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancerA daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades.Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late. More than half of patients are only diagnosed after it has spread. Continue reading…

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancerA daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades.Currently, there are few treatments for pancreatic cancer, and…

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancerA daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades.Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late. More than…

Continue Reading

The full story continues on The Guardian.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.